Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling.
In vivo/preclinical record. Theranostics, 2019.
- Animal
- 2019
Authorship
Exact sentences from the abstract. No machine-written text is on this page. No person reviewed it.
Source: the abstract of PMID 31149039. Checked Verification: Evidence verified by machine against declared source
This study and its findings belong to the authors cited. Defiance International, a supplier of chemical sequences for research use, keeps this record and makes no claim from its findings.
Evidence verified by machine against declared source
Key facts
- Design
- Not reported
- System
- Animal
- Scale
- We compared the expression levels of LL-37 in 45 adjacent normal lung tissues and 86 NSCLC tissues (i.e., 47 adenocarcinomas and 39 squamous cell carcinomas) through immunohistochemistry.
- Comparator
- Present
- Journal
- Theranostics
- Year
- 2019
- PMID
- 31149039
- Verification
- Evidence verified by machine against declared source The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
- Full-text availability
- Abstract only
Technical summary
Research question
We subsequently investigated the levels of LL-37 in the sera of healthy donors and patients diagnosed with NSCLC.
Study design
The animal model of wild-type and Cramp knockout mice was employed to evaluate the tumorigenic effect of LL-37 in non-small cell lung cancer.
Participants or experimental system
The human lung adenocarcinoma cell line A549 and mouse LLC cells were obtained from the American Type Culture Collection, and cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, USA), supplemented with 10% fetal calf serum (Invitrogen, Carlsbad, USA), 100 U/ml penicillin, and 100 U/ml streptomycin (PAA Laboratories GmbH).
Study scale
We compared the expression levels of LL-37 in 45 adjacent normal lung tissues and 86 NSCLC tissues (i.e., 47 adenocarcinomas and 39 squamous cell carcinomas) through immunohistochemistry.
Intervention or exposure
Transfection complexes were removed after 2 h, and cells were stimulated with LL-37 in DMEM supplemented with 0.5% fetal calf serum for 24 h.
Comparator
Treatment with LL-37 caused accumulation of unphosphorylated β-catenin in the nuclei of A549 cells versus untreated cells, exhibiting diffuse localization with a small fraction of unphosphorylated β-catenin in the nuclei (Figure 4D).
Outcomes examined
Methods: The expression of LL-37 in the tissues and sera of patients with non-small cell lung cancer was determined through immunohistological, immunofluorescence analysis, and enzyme-linked immunosorbent assay.
Key findings
Results: LL-37 produced by myeloid cells was frequently upregulated in primary human lung cancer tissues.
Not reported in the declared source: Methods.
Limitations and uncertainty
Not reported in the declared source.
Cite
Cite the study
Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/
Ji P, Zhou Y, Yang Y et al. Theranostics. 2019. PMID 31149039. DOI 10.7150/
The study and its abstract belong to their authors and publisher. Cite them for anything the study found.
Report an error
If a sentence on this record does not match the abstract, tell us which one. A report starts an automatic re-check by machine. No person reads the record first.
The form takes a sentence and your note. It asks for no name and no address, and we store neither. Do not put personal details in the note.
The report form runs in the interactive page. Open this record with scripts enabled to send a report.
Corrections on this record
No correction has been recorded for this record.
Method sheet
No machine-drafted summary is published on this record. Any section shown is the abstract’s own sentence, printed as issued.